NCT04721106 2026-02-10
Korea Post Marketing Surveillance (PMS) Study of Vizimpro
Pfizer
Completed
Clinical Trials
3 trialsNCT04609319 2025-05-31
Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review
Pfizer
Completed
NCT03755102 2025-05-15
A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Completed